Radioembolization With Holmium-166 Polylactic Acid Microspheres: Distribution of Residual Activity in the Delivery Set and Outflow Dynamics During Planning and Treatment Procedures

Purpose: To evaluate the microsphere outflow dynamics and residual Ho-166 activity during and after transarterial radioembolization planning and treatment procedures, and to assess the distribution and predilection sites of residual activity in the proprietary delivery set and the microcatheter. Materials and Methods: Fifteen planning and 12 therapeutic radioembolization procedures were performed with poly-l-lactic acid microspheres loaded with Ho-166. The amount and distribution of residual activity was assessed by dose calibrator measurements and SPECT imaging. The activity flow profile from the microcatheter was assessed dynamically. For planning procedures, different injection methods were evaluated in order to attempt to decrease the residual activity. Results: The median residual activities for planning and treatment procedures using standard injection methods were 31.2% (range 17.3%–44.1%) and 4.3% (range 3.5%–6.9%), respectively. Planning residual activities could be decreased significantly with 2 injection methods similar to treatment procedures, to 17.5% and 10.9%, respectively (P = 0.002). Main predilection sites of residual microspheres were the 3-way stopcock and the outflow needle connector. During treatment procedures, more than 80% of the injected activity is transferred during the first 3 injection cycles. Conclusion: After treatment procedures with holmium-loaded microspheres, mean residual activity in the delivery set is reproducibly low and between reported values for glass and resin microspheres. The majority of microspheres is transferred to the patient during the second and third injection cycle. An estimated residual waste of 3% to 4% may be included in the treatment activity calculation. For planning procedures, a modified injection technique should be used to avoid high residual activities.

[1]  P. Seifert,et al.  Transarterial Radioembolization with Yttrium-90 Glass Microspheres: Distribution of Residual Activity and Flow Dynamics during Administration. , 2020, Journal of vascular and interventional radiology : JVIR.

[2]  P. Seifert,et al.  Ex Vivo Evaluation of Residual Activity and Infusion Dynamics in a Commercially Available Yttrium-90 Resin Microsphere Administration System. , 2019, Journal of vascular and interventional radiology : JVIR.

[3]  Casper Beijst,et al.  The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  J. Nijsen,et al.  The various therapeutic applications of the medical isotope holmium-166: a narrative review , 2019, EJNMMI Radiopharmacy and Chemistry.

[5]  A. Braat,et al.  Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. , 2019, Seminars in nuclear medicine.

[6]  G. Krijger,et al.  Blood and urine analyses after radioembolization of liver malignancies with [166Ho]Ho-acetylacetonate-poly(l-lactic acid) microspheres. , 2019, Nuclear medicine and biology.

[7]  M. A. van den Bosch,et al.  Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study , 2017, The Journal of Nuclear Medicine.

[8]  Marnix G. E. H. Lam,et al.  Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study , 2017, European Radiology.

[9]  H. Schild,et al.  Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5 % glucose during administration , 2015, EJNMMI Research.

[10]  Marnix G E H Lam,et al.  Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres , 2015, The Journal of Nuclear Medicine.

[11]  T. Chua,et al.  Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature , 2014, Journal of medical imaging and radiation oncology.

[12]  M. Viergever,et al.  99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  D. Eschelman,et al.  Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[14]  M. A. van den Bosch,et al.  Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. , 2012, The Lancet. Oncology.

[15]  M. A. van den Bosch,et al.  Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial , 2010, Journal of experimental & clinical cancer research : CR.

[16]  M. A. van den Bosch,et al.  Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: technical aspects studied in a large animal model , 2009, European Radiology.

[17]  J. Seppenwoolde,et al.  Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(l-lactic acid) microspheres in healthy pigs , 2008, European Journal of Nuclear Medicine and Molecular Imaging.